Neuroprotective strategies in Alzheimer’s disease

Longo, Frank M.; Massa, Stephen M.

doi:10.1602/neurorx.1.1.117

Cited by 83Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesNeurological Disorders and Treatments

Neuroprotective strategies in Alzheimer’s disease

Open access

Longo, Frank M., Massa, Stephen M.·2004·NeuroRx

DOI 10.1602/neurorx.1.1.117PMC PMC534917

Open this paper in CoChat — free account

Abstract

In addition to strategies designed to decrease amyloid beta (A beta) levels, it is likely that successful Alzheimer's disease (AD) therapeutic regimens will require the concomitant application of neuroprotective agents. Elucidation of pathophysiological processes occurring in AD and identification of the molecular targets mediating these processes point to potential high-yield neuroprotective strategies. Candidate neuroprotective agents include those that interact specifically with neuronal targets to inhibit deleterious intraneuronal mechanisms triggered by A beta and other toxic stimuli. Strategies include creating small molecules that block A beta interactions with cell surface and intracellular targets, down-regulate stress kinase signaling cascades, block activation of caspases and expression of pro-apoptotic proteins, and inhibit enzymes mediating excessive tau protein phosphorylation. Additional potential neuroprotective compounds include those that counteract loss of cholinergic function, promote the trophic state and plasticity of neurons, inhibit accumulation of reactive oxygen species, and block excitotoxicity. Certain categories of compounds, such as neurotrophins or neurotrophin small molecule mimetics, have the potential to alter neuronal signaling patterns such that several of these target actions might be achieved by a single agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1602/neurorx.1.1.117

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of molecular targets mediating pathophysiological processes could potentially allow the development of high-yield neuroprotective techniques for Alzheimer's disease treatment.
“The identification of these targets could potentially allow the development of high-yield neuroprotective techniques for AD treatment [35].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [35]
Various molecular targets have been recognized as mediating pathophysiological processes.
“As of now, various molecular targets have been recognized as mediating pathophysiological processes [35].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [35]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · see citing works
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · see citing works
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · see citing works
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works
Apoptosis in the nervous system
Yuan, J., & Yankner, B. A. (2000) · Nature · doi:10.1038/35037739 · Cited by 1,862 · see citing works
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,774 · see citing works
The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530 · see citing works
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · see citing works
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315 · see citing works
Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · see citing works
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080 · see citing works
Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898 · see citing works
Oxidative stress in brain agingImplications for therapeutics of neurodegenerative diseases
Floyd, R. A., & Hensley, K. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00019-2 · Cited by 830 · see citing works
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 816 · see citing works
Amyloid β-peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer's Disease Brain. A Review
Allan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786 · see citing works
Neurotrophin Signaling Through the P75 Neurotrophin Receptor
Roux, P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00016-3 · Cited by 717 · see citing works
Intraneuronal Alzheimer Aβ42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706 · see citing works
Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678 · see citing works
Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 669 · see citing works
Increase of Brain Oxidative Stress in Mild Cognitive Impairment
Praticò, D., Clark, C. M., Liun, F., Lee, V., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 587 · see citing works
Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.
Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas‐Kramarski, R., JAFFE, E. A., Gandy, S., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10075 · Cited by 558 · see citing works
β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand
MORISHIMA, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R. A., Davis, R. J., Shirasaki, Y., & Greenberg, M. E. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07551.2001 · Cited by 484 · see citing works
The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease.
Fahnestock, M., Michalski, B., Xu, B., & Coughlin, M. (2001) · Molecular and cellular neurosciences · doi:10.1006/mcne.2001.1016 · Cited by 482 · see citing works
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472 · see citing works
Activation and redistribution of c‐Jun N‐terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease
Zhu, X.-W., Raina, A., Rottkamp, C., Aliev, G., Perry, G., Boux, H., & Smith, M. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00046.x · Cited by 440 · see citing works
The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3
Chen, G., Huang, L., Jiang, Y., & Manji, H. K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0721327.x · Cited by 439 · see citing works
Mitochondria, free radicals, and neurodegeneration
Beal, M. F. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80100-0 · Cited by 422 · see citing works
Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons
Zhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110119 · Cited by 418 · see citing works
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · see citing works
α7 Nicotinic Receptor Transduces Signals to Phosphatidylinositol 3-Kinase to Block A β-Amyloid-induced Neurotoxicity
Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Shibasaki, H., Kume, T., & Akaike, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008035200 · Cited by 412 · see citing works
Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.
Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H., & Selkoe, D. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49409-x · Cited by 399 · see citing works
Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF
Mattson, M. P., Tomaselli, K. J., & Rydel, R. E. (1993) · Brain Research · doi:10.1016/0006-8993(93)90295-x · Cited by 379 · see citing works
Calcium and Excitotoxic Neuronal Injury
Choi, D. W. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44407.x · Cited by 344 · see citing works
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease
Coyle, J. T., & Kershaw, P. R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 337 · see citing works
Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion
Cooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · see citing works
A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · see citing works
Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity
Doré, S., Kar, S., & Quirion, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4772 · Cited by 325 · see citing works
The many faces of p75NTR
Hempstead, B. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00321-5 · Cited by 321 · see citing works
Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus
Knipper, M., da Penha Berzaghi, M., Blöchl, A., Breer, H., Thoenen, H., & Lindholm, D. (1994) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1994.tb00312.x · Cited by 298 · see citing works
Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases
Mufson, E. J., Kroin, J. S., Sendera, T. J., & Sobreviela, T. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00059-8 · Cited by 296 · see citing works
Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition
Savage, M. J., Lin, Y.-G., Ciallella, J. R., Flood, D. G., & Scott, R. W. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03376.2002 · Cited by 291 · see citing works
Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
Parsons, C. G., Gruner, R., Rozental, J., Millar, J. D., & Lodge, D. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90029-3 · Cited by 279 · see citing works
The Glutamatergic System and Alzheimer???s Disease
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267 · see citing works
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265 · see citing works
The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons
Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., & Pearson, H. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05531.2003 · Cited by 248 · see citing works
Role of neurotrophins in central synapse formation and stabilization
Vicario‐Abejón, C., Owens, D. F., McKay, R. D. G., & Segal, M. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn988 · Cited by 247 · see citing works
beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation
Troy, C. M., Rabacchi, S. A., Xu, Z., Maroney, A. C., Connors, T. J., Shelanski, M. L., & Greene, L. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00218.x · Cited by 223 · see citing works
Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases.
Deshmukh, M., Vasilakos, J. P., Deckwerth, T. L., Lampe, P. A., Shivers, B. D., & Johnson, E. M. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.135.5.1341 · Cited by 221 · see citing works
Ultrastructural Localization of Full-Length trkB Immunoreactivity in Rat Hippocampus Suggests Multiple Roles in Modulating Activity-Dependent Synaptic Plasticity
Drake, C. T., Milner, T. A., & Patterson, S. L. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-18-08009.1999 · Cited by 221 · see citing works
H2o2 and 4-hydroxynonenal mediate amyloid β-induced neuronal apoptosis by activating jnks and p38mapk
Tamagno, E., Robino, G., Obbili, A., Bardini, P., Aragno, M., Parola, M., & Danni, O. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(02)00059-6 · Cited by 201 · see citing works
Alzheimer's Disease: Biology, Diagnosis and Therapeutics
Hier, D. B. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00025 · Cited by 200 · see citing works
The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling
Roßner, S. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00044-6 · Cited by 195 · see citing works
Antioxidant strategies for Alzheimer's disease
Grundman, M., & Delaney, P. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2002146 · Cited by 193 · see citing works
Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease.
Mufson, E. J., & Kordower, J. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.569 · Cited by 190 · see citing works
Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I Protection
Wei, W., Wang, X., & Kusiak, J. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111704200 · Cited by 190 · see citing works
Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain
Smith, M. A., Casadesús, G., Joseph, J. A., & Perry, G. L. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01021-3 · Cited by 189 · see citing works
Neuronal Apoptosis Induced by β-Amyloid Is Mediated by Caspase-8
Ivins, K. J., Thornton, P. L., Rohn, T. T., & Cotman, C. W. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0268 · Cited by 187 · see citing works
Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh
Ole Isacson, A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02037-4 · Cited by 187 · see citing works
Alzheimer’s disease and oxygen radicals: new insights
Praticò, D. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00919-4 · Cited by 186 · see citing works
Local neuroinflammation and the progression of Alzheimer’s disease
McGeer, P., & Mcgeer, E. (2011) · Journal of Neurovirology · doi:10.1080/13550280290100969 · Cited by 181 · see citing works
Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation
Marques, C. A., Keil, U., Bonert, A., Steiner, B., Haass, C., Müller, W. E., & Eckert, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212265200 · Cited by 175 · see citing works
Caspases, Apoptosis, and Alzheimer Disease: Causation, Correlation, and Confusion
Roth, K. A. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.9.829 · Cited by 175 · see citing works
Nerve growth factor potentiates the neurotoxicity of beta amyloid.
Yankner, B. A., Cáceres, A., & Duffy, L. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.9020 · Cited by 171 · see citing works
JNK activation is associated with intracellular β-amyloid accumulation
Shoji, M., Iwakami, N., Takeuchi, S., Waragai, M., Suzuki, M., Kanazawa, I., Lippa, C. F., Ono, S., & Okazawa, H. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00245-x · Cited by 166 · see citing works
Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3107 · Cited by 165 · see citing works
Alzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164 · see citing works
Estrogen‐mediated neuroprotection against β‐amyloid toxicity requires expression of estrogen receptor α or β and activation of the MAPK pathway
Fitzpatrick, J. L., Mize, A. L., Wade, C. B., Harris, J. A., Shapiro, R. A., & Dorsa, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01000.x · Cited by 156 · see citing works
CEP‐1347/KT‐7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ‐induced cortical neuron apoptosis
Bozyczko‐Coyne, D., O’Kane, T. M., Wu, Z.-L., Dobrzański, P., Murthy, S., Vaught, J. L., & Scott, R. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00294.x · Cited by 151 · see citing works
Akt (Protein Kinase B) Negatively Regulates SEK1 by Means of Protein Phosphorylation
Park, H.-S., Kim, M.-S., Huh, S.-H., Park, J., Chung, J., Kang, S. S., & Choi, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110299200 · Cited by 144 · see citing works
Alzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317527 · Cited by 139 · see citing works
Aberrant Tau Phosphorylation by Glycogen Synthase Kinase-3β and JNK3 Induces Oligomeric Tau Fibrils in COS-7 Cells*
Sato, S., Tatebayashi, Y., Akagi, T., Chui, D., Murayama, M., Miyasaka, T., Planel, E., Tanemura, K., Sun, X.-Y., Hashikawa, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202241200 · Cited by 132 · see citing works
Traffic at the intersection of neurotrophic factor signaling and neurodegeneration
Salehi, A., Delcroix, J.-D., & Mobley, W. C. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)00038-3 · Cited by 131 · see citing works
Rapid suppression of free radical formation by nerve growth factor involves the mitogen-activated protein kinase pathway
Dugan, L. L., Creedon, D. J., Johnson, E. M., & Holtzman, D. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4086 · Cited by 128 · see citing works
Multiple caspases are involved in β‐amyloid‐induced neuronal apoptosis
Allen, J. W., Eldadah, B. A., Huang, X., Knoblach, S. M., & Faden, A. I. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1126 · Cited by 127 · see citing works
Growth-factor gene therapy for neurodegenerative disorders
Tuszynski, M. H. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00006-6 · Cited by 125 · see citing works
Development of pharmacological agents for targeting neurotrophins and their receptors
Saragovi, H. U., & Gehring, K. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01444-3 · Cited by 121 · see citing works
Regulation of tau phosphorylation and protection against β‐amyloid‐induced neurodegeneration by lithium. Possible implications for Alzheimer's disease
Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Ávila, J., Bogónez, E., & Díaz‐Nido, J. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01150.x · Cited by 116 · see citing works
β-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimerʼs disease
Harris‐White, M. E., Carney, J. M., Cole, P. S., Hensley, K., Howard, B. J., Martin, L., Bummer, P. M., Wang, Y., Pedigo, N. W., & Butterfield, D. A. (1995) · Neuroreport · doi:10.1097/00001756-199510020-00013 · Cited by 112 · see citing works
Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease
Höck, C., Maddalena, A. S., Raschig, A., Müller-Spahn, F., Eschweiler, G. W., Huger, K., Hewer, I., Hampel, H. J., Müller-Thornsen, T., Oertel, W. H., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 110 · see citing works
Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
Lin, L., Georgievska, B., Mattsson, A., & Ole Isacson, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12108 · Cited by 110 · see citing works
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108 · see citing works
Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate
Erdö, S. L., & Schäfer, M. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90625-z · Cited by 105 · see citing works
Inhibition of the c-Jun N-Terminal Kinase Signaling Pathway by the Mixed Lineage Kinase Inhibitor CEP-1347 (KT7515) Preserves Metabolism and Growth of Trophic Factor-Deprived Neurons
Harris, C. A., Deshmukh, M., Pierchala, B. A., Maroney, A. C., & Johnson, E. M. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00103.2002 · Cited by 102 · see citing works
Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients.
Hu, X.-Y., Zhang, H.-Y., Qin, S., Xu, H.-W., Swaab, D., & Zhou, J.-N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8018 · Cited by 98 · see citing works
A New Concept in the Pharmacology of Neuroprotection
Gozes, I., & Brenneman, D. E. (2000) · Journal of Molecular Neuroscience · doi:10.1385/jmn:14:1-2:061 · Cited by 90 · see citing works
β-Amyloid Plaques in a Model for Sporadic Alzheimer's Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies
Capsoni, S., Giannotta, S., & Cattaneo, A. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1163 · Cited by 90 · see citing works
The role of tau in Alzheimer's disease
Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00002-0 · Cited by 85 · see citing works
Nerve Growth Factor (NGF) Loop 4 Dimeric Mimetics Activate ERK and AKT and Promote NGF-like Neurotrophic Effects
Xie, Y., Tisi, M. A., Yeo, T. T. S., & Longo, F. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005071200 · Cited by 85 · see citing works
Self-citation
Ten years on: mediation of cell death by the common neurotrophin receptor p75NTR
Rabizadeh, S., & Bredesen, D. E. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00018-2 · Cited by 82 · see citing works
AF150(S) and AF267B
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 80 · see citing works
Death and survival of neuronal cells exposed to Alzheimer's insults
Niikura, T., Hashimoto, Y., Tajima, H., & Nishimoto, I. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10354 · Cited by 76 · see citing works
Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors
Hellström‐Lindahl, E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00028-5 · Cited by 75 · see citing works
Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial
Farlow, M. R., Potkin, S. G., Koumaras, B., Veach, J., & Mirski, D. F. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.843 · Cited by 72 · see citing works
Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease
Bozyczko‐Coyne, D., Saporito, M. S., & Hudkins, R. L. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339472 · Cited by 68 · see citing works
Mechanisms of Amyloid β Protein-Induced Modification in Ion Transport Systems: Implications for Neurodegenerative Diseases
Kourie, J. I. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1010932603406 · Cited by 67 · see citing works
Coupling of the p75 Neurotrophin Receptor to Sphingolipid Signalinga
Dobrowsky, R. T., & Carter, B. D. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09660.x · Cited by 66 · see citing works
A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons
Fogarty, M. P., Downer, E. J., & Campbell, V. A. (2003) · Biochemical Journal · doi:10.1042/bj20021660 · Cited by 65 · see citing works
Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00158-8 · Cited by 64 · see citing works
Expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 in the somatosensory cortex of the mature rat: Coexpression with high-affinity neurotrophin receptors
Pitts, A. F., & Miller, M. W. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000313)418:3 · Cited by 61 · see citing works
Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits: a minireview
Tran, M. H., Yamada, K., & Nabeshima, T. (2002) · Peptides · doi:10.1016/s0196-9781(02)00062-1 · Cited by 61 · see citing works
Alterations in Trk A, Trk B and Trk C Receptor Immunoreactivities in Parietal Cortex and Cerebellum in Alzheimer’s Disease
Savaskan, E., Müller-Spahn, F., Olivieri, G., Bruttel, S., Otten, U., Rosenberg, C., Hulette, C., & Höck, C. (2000) · European Neurology · doi:10.1159/000008229 · Cited by 58 · see citing works
Molecular Mechanisms for Neuronal Cell Death by Alzheimer’s Amyloid Precursor Protein-Relevant Insults
Kawasumi, M., Hashimoto, Y., Chiba, T., Kanekura, K., Yamagishi, Y., Ishizaka, M., Tajima, H., Niikura, T., & Nishimoto, I. (2002) · Neurosignals · doi:10.1159/000067424 · Cited by 53 · see citing works
Caspase activation in the Alzheimer's disease brain: Tortuous and torturous
Rohn, T. T., Rissman, R. A., Head, E., & Cotman, C. W. (2002) · Drug News & Perspectives · doi:10.1358/dnp.2002.15.9.740233 · Cited by 48 · cited 2× · see citing works
“In contrast to this view, the finding of caspase activation in early stages of AD and in association with neurofibrillary tangles suggests that caspases might serve as a link between senile plaques and tangles and contribute to early as well as terminal steps of cell death.(38)”
BackgroundResult
Inflammation takes on Alzheimer disease
Golde, T. E. (2002) · Nature Medicine · doi:10.1038/nm0902-936 · Cited by 45 · see citing works
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Foley, D. J., & White, L. R. (2002) · JAMA · doi:10.1001/jama.287.24.3261 · Cited by 44 · see citing works
Neuroprotective Properties of Valproate : Potential Benefit for AD and Tauopathies
Loy, R., & Tariot, P. N. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:19:3:301 · Cited by 43 · see citing works
Glumate Receptor Dysfunction and Alzheimer's Disease
Olney, J. W., Wozniak, D. F., & Farber, N. B. (1998) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-1998-00048 · Cited by 41 · see citing works
Neurotrophin small-molecule mimetics
Me, Y., & Longo, F. M. (2000) · Progress in brain research · doi:10.1016/s0079-6123(00)28030-8 · Cited by 40 · see citing works
Self-citation
Alzheimer's Therapeutics: Neurotrophin Domain Small Molecule Mimetics
Massa, S. M., Xie, Y., & Longo, F. M. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:323 · Cited by 39 · see citing works
Self-citation
Alzheimer’s therapeutics
Massa, S. M., Xie, Y., & Longo, F. M. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0019-1 · Cited by 39 · see citing works
Self-citation
Detection of the peripheral nervous system (PNS)-type glial fibrillary acidic protein (GFAP) and its mRNA in human lymphocytes
Riol, H., Tardy, M., Rolland, B., L�vesque, G., & Murthy, M. R. V. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970401)48:1 · Cited by 38 · see citing works
The Pathogenesis of Alzheimer's Disease: Is Amyloid β‐Protein the Beginning or the End?
Yankner, B. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05555.x · Cited by 36 · see citing works
Ironic Fate
Cole, G. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00160-0 · Cited by 21 · see citing works
Amyloid peptide toxicity and microtubule-stabilizing drugs
Michaelis, M. L., Chen, Y., Hill, S., Reiff, E., Georg, G. I., Rice, A., & Audus, K. L. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0018-2 · Cited by 21 · see citing works
Modulation of Sensory Inputs and Ectopic Presence of Schwann Cells Depend upon the Route and Duration of Nerve Growth Factor Administration
Pizzo, D. P., Winkler, J., Sidiqi, I., Waite, J. J., & Thal, L. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8010 · Cited by 11 · see citing works
Tau as a Drug Target in Alzheimer's Disease
Gozes, I. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:19:3:337 · Cited by 11 · see citing works
569 Long-term treatment of Alzheimer's disease with idebenone
Gutzmann, H., Erzigkeit, H., & Hadler, D. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)80571-9 · Cited by 9 · see citing works
Untitled work
(2000) · doi:10.1002/1531-8249(200012)48:6

Flagged first, then by citations

Sorted by citations

Neuroprotective Natural Products for Alzheimer’s Disease
Chen, X., Drew, J., Berney, W., & Lei, W. (2021) · Cells · doi:10.3390/cells10061309 · Cited by 236 · see citing works
The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy<i>In Vitro</i>and<i>In Vivo</i>
Knowles, J. K., Rajadas, J., Nguyen, T.-V. V., Yang, T., LeMieux, M. C., Vander Griend, L., Ishikawa, C., Massa, S. M., Wyss-Coray, T., & Longo, F. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0620-09.2009 · Cited by 184 · see citing works
Self-citation
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works
“The identification of these targets could potentially allow the development of high-yield neuroprotective techniques for AD treatment [35].”
Background

Neuroprotective Effects of Daphnetin against NMDA Receptor-Mediated Excitotoxicity
Yang, L., Yang, Q., Zhang, K., Li, Y., Wu, Y., Liu, S., Zheng, L., & Zhao, M. (2014) · Molecules · doi:10.3390/molecules190914542 · Cited by 36 · see citing works
Neuroprotective Effects of Thymosin β4 in Experimental Models of Excitotoxicity
Popoli, P., Pepponi, R., Martire, A., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1415.033 · Cited by 35 · see citing works
Excitotoxicity‐induced endocytosis mediates neuroprotection by TAT‐peptide‐linked JNK inhibitor
Vaslin, A., Naegele‐Tollardo, S., Puyal, J., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07535.x · Cited by 20 · see citing works
Pharmacological strategies related to ocular neuroprotection
Garhöfer, G. (2013) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2013.1641.x
Decoding signaling pathways involved in prolactin-induced neuroprotection: A review
Molina-Salinas, G., Rivero-Segura, N. A., Cabrera-Reyes, E. A., Rodríguez-Chávez, V., Langley, E., & Cerbón, M. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100913 · Cited by 31 · see citing works

Authors: Longo, F. M., & Massa, S. M.
Affiliations: University of North Carolina at Chapel Hill (US)
San Francisco VA Medical Center (US)
Corresponding author: Longo, Frank M.
ORCID: Longo, Frank M.
Massa, Stephen M.
Venue: NeuroRx
Publisher: Springer Science and Business Media LLC
Published: 2004-01
Volume: 1
Issue: 1
Pages: 117-127
ISSN: 1545-5343 (ISSN-L)
DOI: 10.1602/neurorx.1.1.117
PMC: PMC534917
OpenAlex: W2014865029
Cited by: 83
References: 120
Citations by year: 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 4 · 2013: 5 · 2012: 3
FWCI: 0.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: NeuroRx (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
National Institute on Aging (R01AG009873, R01-AG09873)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords: Alzheimer's disease, neuroprotection, amyloid-beta, neuroprotective agents, caspase inhibition, apoptosis, tau phosphorylation, cholinergic dysfunction, reactive oxygen species, excitotoxicity, neurotrophins, small molecule mimetics, neuroplasticity
MeSH terms: Alzheimer Disease, Animals, Brain, Humans, Signal Transduction, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuroprotective strategies in Alzheimer’s disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks